SCHEMBL659365

SCHEMBL659365

NCCc1nccs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17184356 0.98 ALDH1A1 (0.42)
Hydrochloric Acid SCHEMBL1028586 0.98
Acetaldehyde SCHEMBL7630487 0.88 CYP2C19 (0.39)
SCHEMBL2170936 0.86
SCHEMBL8671012 0.85 FDPS (0.47)
SCHEMBL8560648 0.85 HRH1 (0.40)
Hydrochloric Acid SCHEMBL27275786 0.85 TSHR (0.39)
Hydrochloric Acid SCHEMBL17184529 0.85 TSHR (0.39)
SCHEMBL627047 0.83 HRH1 (0.43)
SCHEMBL69929 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673146-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS Biohaven Therapeutics Ltd. (VG) 2026-01-07 EP claimed
WO-2024182465-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS ALCO THERAPEUTICS, LLC (US) 2024-09-06 WO claimed
US-20160000777-A1 METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS UNIVERSITY OF ROCHESTER (US) 2016-01-07 US claimed
EP-2627631-B1 PYRROLIDINONES AS METAP2 INHIBITORS MERCK PATENT GMBH (DE) 2015-12-16 EP claimed
WO-2014130759-A1 METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS UNIVERSITY OF ROCHESTER (US) 2014-08-28 WO claimed
US-20070086981-A1 Delivery peptides, their constructs with active agents and use ORTHOGEN AG (DE) 2007-04-19 US claimed
WO-2007001406-A2 ARYL-CONTAINING MACROCYCLIC COMPOUNDS CHIRON CORPORATION (US) 2007-01-04 WO claimed
EP-1694696-A1 DELIVERY PEPTIDES ,THEIR CONSTRUCTS WITH ACTIVE AGENTS AND USE ORTHOGEN Aktiengesellschaft (DE) 2006-08-30 EP claimed
WO-2005054279-A1 DELIVERY PEPTIDES, THEIR CONSTRUCTS WITH ACTIVE AGENTS AND USE ORTHOGEN AG (DE) 2005-06-16 WO claimed
US-5116856-A AMINOETHYLTHIAZOLE AND AMINOETHYLOXAZOLE DERIVATIVES AKZO N.V. (NL) 1992-05-26 US claimed
EP-0385525-A1 Aminoethylthiazole and aminoethyloxazole derivatives Akzo Nobel N.V. (NL) 1990-09-05 EP claimed
US-4474876-A Flow cytometric analysis of histamine receptors TRUSTEES OF BOSTON UNIVERSITY (US) 1984-10-02 US claimed
JP-2273664-A None JP disclosed
US-20260070903-A1 NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-12 US disclosed
EP-4673146-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS Biohaven Therapeutics Ltd. (VG) 2026-01-07 EP disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
EP-0271829-A2 Delta-hydroxy-beta-lysine derivatives and their production Takeda Chemical Industries, Ltd. (JP) 1988-06-22 EP disclosed
US-4474876-A Flow cytometric analysis of histamine receptors TRUSTEES OF BOSTON UNIVERSITY (US) 1984-10-02 US disclosed
US-4228176-A ANTIINFLAMMATORY AGENT NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1980-10-14 US disclosed
US-4172139-A CARDIOVASCULAR DISORDERS NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1979-10-23 US disclosed